{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T23:25:28Z","timestamp":1784417128993,"version":"3.55.0"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/AuthorWarrantyLicense.v1"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201500005I"],"award-info":[{"award-number":["HHSN272201500005I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,11,17]]},"abstract":"<jats:p>\n            Zoliflodacin is a novel spiropyrimidinetrione antibiotic being developed as single oral dose treatment to address the growing global threat of\n            <jats:named-content content-type=\"genus-species\">Neisseria gonorrhoeae<\/jats:named-content>\n            . To evaluate the cardiac safety of zoliflodacin, a thorough QT\/QTc (TQT) study was performed in healthy subjects.\n          <\/jats:p>","DOI":"10.1128\/aac.01292-21","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T16:52:42Z","timestamp":1633366362000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-5208","authenticated-orcid":true,"given":"Lori M.","family":"Newman","sequence":"first","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kankam","sequence":"additional","affiliation":[{"name":"Altasciences Clinical Kansas, Inc., Overland Park, Kansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Emmes Company, LLC, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Conrad","sequence":"additional","affiliation":[{"name":"Emmes Company, LLC, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mueller","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaire L.","family":"Osborn","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Gu","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Saviolakis","sequence":"additional","affiliation":[{"name":"DynPort Vaccine Company, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.18.228486"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1071\/SH19023"},{"key":"e_1_3_3_4_2","unstructured":"US Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2019. https:\/\/www.cdc.gov\/std\/statistics\/2019\/figures\/GISP-2.htm."},{"key":"e_1_3_3_5_2","volume-title":"WHO guidelines for the treatment of Neisseria gonorrhoeae.","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. WHO guidelines for the treatment of Neisseria gonorrhoeae. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6950a6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.663534"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep11827"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04124-14"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03920-14"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01808-18"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00021"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706988"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.34141"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0751-2"},{"key":"e_1_3_3_17_2","volume-title":"Guidance for industry. S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals.","author":"FDA","year":"2005","unstructured":"FDA. 2005. Guidance for industry. S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. FDA, Rockville, MD."},{"key":"e_1_3_3_18_2","volume-title":"Guidance for industry. E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.","author":"FDA","year":"2005","unstructured":"FDA. 2005. Guidance for industry. E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. FDA, Rockville, MD."},{"key":"e_1_3_3_19_2","volume-title":"Guidance for industry. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs\u2014questions and answers (R3), revision 2.","author":"FDA","year":"2017","unstructured":"FDA. 2017. Guidance for industry. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs\u2014questions and answers (R3), revision 2. FDA, Rockville, MD."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286150503900408"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2006.09.003"},{"key":"e_1_3_3_22_2","volume-title":"Chou\u2019s electrocardiography in clinical practice","author":"Surawicz B","year":"2008","unstructured":"Surawicz B, Knilans TK. 2008. Chou\u2019s electrocardiography in clinical practice, 6th ed. Saunders Elsevier, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.282"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00427.x19775279"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127001037840820978278"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007307881"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01292-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01292-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:37:24Z","timestamp":1645486644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01292-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11,17]]}},"alternative-id":["10.1128\/AAC.01292-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01292-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"2021-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01292-21"}}